Key Takeaways
- • Cagent Vascular closed a $41 million Series D financing round co-led by U.S. Venture Partners (USVP) and Astoria Health Investors, funding the global REMODEL II pivotal trial and commercial launch of the Serranator® SONIC Intravascular Lithotripsy (IVL) System.
- • The company achieved first human-use cases with the SONIC IVL System and has already established commercial footing with its Serranator® portfolio sold across most major U.S. markets and select international markets.
- • Series D proceeds will support both the SONIC IVL System's global expansion and development of the company's coronary artery platform, broadening its addressable market beyond peripheral artery applications.
- • Cagent Vascular operates in the endovascular technology space, pioneering Serration Remodeling Therapy (SRT) to improve vessel preparation and treatment outcomes for patients with Peripheral Artery Disease (PAD) and Chronic Limb-Threatening Ischemia (CLTI).
Summary
Cagent Vascular, a Pennsylvania-based endovascular technology company, announced the closing of a $41 million Series D financing round led jointly by U.S. Venture Partners and Astoria Health Investors. The capital infusion marks a significant milestone for the company as it accelerates commercialization and clinical development of its proprietary intravascular lithotripsy platform.
The funding proceeds will primarily support two strategic initiatives: the global REMODEL II pivotal trial and the commercial launch of the Serranator® SONIC Intravascular Lithotripsy System. The SONIC IVL platform represents an advancement in endovascular intervention technology, with the company achieving first human-use cases prior to the Series D close. Additionally, the capital will fund development of the company's coronary artery platform, signaling expansion beyond its current peripheral vascular focus.
Cagent Vascular operates in a defined niche within interventional cardiology and vascular medicine. The company is pioneering Serration Remodeling Therapy (SRT), a differentiated approach to balloon angioplasty that uses integrated serrations on the balloon surface to improve vessel preparation and treatment outcomes. This positioning addresses clinical needs in patients with Peripheral Artery Disease (PAD) and Chronic Limb-Threatening Ischemia (CLTI), conditions with significant unmet treatment needs and large patient populations.
The company has already established commercial traction prior to this funding round. The Serranator® portfolio is currently sold nationally across most major U.S. markets and in select international markets, providing revenue-generating operations that de-risk the Series D deployment. The combination of existing commercial presence, clinical validation through first human-use cases, and committed institutional capital positions Cagent Vascular for scaled market penetration and potential multi-indication expansion into coronary applications.
The funding proceeds will primarily support two strategic initiatives: the global REMODEL II pivotal trial and the commercial launch of the Serranator® SONIC Intravascular Lithotripsy System. The SONIC IVL platform represents an advancement in endovascular intervention technology, with the company achieving first human-use cases prior to the Series D close. Additionally, the capital will fund development of the company's coronary artery platform, signaling expansion beyond its current peripheral vascular focus.
Cagent Vascular operates in a defined niche within interventional cardiology and vascular medicine. The company is pioneering Serration Remodeling Therapy (SRT), a differentiated approach to balloon angioplasty that uses integrated serrations on the balloon surface to improve vessel preparation and treatment outcomes. This positioning addresses clinical needs in patients with Peripheral Artery Disease (PAD) and Chronic Limb-Threatening Ischemia (CLTI), conditions with significant unmet treatment needs and large patient populations.
The company has already established commercial traction prior to this funding round. The Serranator® portfolio is currently sold nationally across most major U.S. markets and in select international markets, providing revenue-generating operations that de-risk the Series D deployment. The combination of existing commercial presence, clinical validation through first human-use cases, and committed institutional capital positions Cagent Vascular for scaled market penetration and potential multi-indication expansion into coronary applications.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.